Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Gynaecological cancers 1

810MO - Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial


18 Sep 2020


Mini Oral - Gynaecological cancers 1


Tumour Site

Ovarian Cancer


Bhavana Pothuri


Annals of Oncology (2020) 31 (suppl_4): S551-S589. 10.1016/annonc/annonc276


B. Pothuri1, S. Han2, D. Chase3, F. Heitz4, R. Burger5, L. Gaba6, L. Van Le7, E. Guerra8, D. Bender9, J. Korach10, N.G. Cloven11, P. Follana12, J. Baurain13, C. Pisano14, U. Peen15, J. Maenpaa16, E. Bacqué17, Y. Li18, A. González Martín19, B.J. Monk3

Author affiliations

  • 1 Department Of Obstetrics/gynecology, Gynecologic Oncology Group (GOG) and Perlmutter Cancer Center, NYU Langone Health, 10016 - New York/US
  • 2 Department Of Obstetrics And Gynecology, University Hospitals Leuven, Leuven/BE
  • 3 Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix/US
  • 4 Department For Gynecology And Gynecologic Oncology, Kliniken Essen-Mitte, Essen/DE
  • 5 Obstetrics And Gynecology, University of Pennsylvania, Philadelphia/US
  • 6 Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona/ES
  • 7 Department Of Obstetrics/gynecology, University of North Carolina at Chapel Hill, Chapel Hill/US
  • 8 Medical Oncology Department, Breast and Gynecological Cancer Unit, Hospital Ramon y Cajal, Madrid/ES
  • 9 Department Of Obstetrics And Gynecology, University of Iowa, Iowa City/US
  • 10 Department Of Oncology, Chaim Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan/IL
  • 11 Gynecologic Oncology Department, Texas Oncology, 76104 - Fort Worth/US
  • 12 Medical Oncology, GINECO and Centre Anticancer Antoine Lacassagne, Nice/FR
  • 13 Medical Oncology, Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels/BE
  • 14 Department Of Urology And Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples/IT
  • 15 Medical Oncology, Hervlev University Hospital, Hervlev/DK
  • 16 Gynecologic Oncology, Tampere University Hospital, 33521 - Tampere/FI
  • 17 Clinical Science, GlaxoSmithKline, Waltham/US
  • 18 Clinical Science, GlaxoSmithKline, waltham/US
  • 19 Medical Oncology Department, Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Clínica Universidad de Navarra, 28027 - Madrid/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 810MO


Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that is approved for use in heavily pretreated pts and as maintenance treatment of pts with newly diagnosed or recurrent ovarian cancer following a response to platinum-based chemotherapy (CT). Here we report PROs in pts receiving niraparib and placebo (PBO) in the PRIMA/ENGOT-OV26/GOG-3012 trial.


This double-blind, PBO-controlled, phase III study randomized 733 pts with newly diagnosed advanced ovarian, primary peritoneal, or fallopian tube cancer with a complete or partial response (CR or PR) to first-line (1L) platinum-based CT. Pts received niraparib or PBO once daily for 36 months or until disease progression. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. PROs, a secondary endpoint, were collected every 8 weeks for 56 weeks, then every 12 weeks thereafter while treatment was ongoing. Once a pt discontinued treatment, PRO evaluations were performed at the time of treatment discontinuation and then at 4, 8, 12, and 24 weeks (±1 week for each time point) after the end of treatment, regardless of the status of subsequent treatment. The validated PRO instruments utilized were FOSI, EQ-5D-5L, EORTC-QLQ-C30, and EORTC-QLQ-OV28.


Compliance rates were high for all of the PRO instruments used in the study. PRO analysis of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 did not indicate a difference in health-related quality of life scores of pts treated with niraparib vs placebo. Mean scores between niraparib and placebo arms were similar at each time point. Overall, the health utility index showed a slight improvement trend in pts who received niraparib vs placebo.


Consistent with PRO results in the NOVA study, pts receiving niraparib in the PRIMA trial did not experience a decrease in quality of life compared with those receiving placebo.

Clinical trial identification


Editorial acknowledgement

Writing and editorial support, funded by GlaxoSmithKline (Waltham, MA, USA) and coordinated by Ashujit Tagde, PhD of GlaxoSmithKline, was provided by Eric Scocchera, PhD and Anne Cooper, MA of Ashfield Healthcare Communications (Middletown, CT, USA).

Legal entity responsible for the study

GlaxoSmithKline, Waltham, MA, USA.


GlaxoSmithKline, Waltham, MA, USA.


B. Pothuri: Advisory/Consultancy, Research grant/Funding (institution), Non-remunerated activity/ies: Tesaro; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Clovis Oncology. D. Chase: Speaker Bureau/Expert testimony: Tesaro. F. Heitz: Non-remunerated activity/ies: NewOncology; Advisory/Consultancy: Roche; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Clovis; Advisory/Consultancy: Tesaro; Advisory/Consultancy: PharmaMar. R. Burger: Advisory/Consultancy: Amgen; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Tesaro; Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy: Genentech; Advisory/Consultancy: Gradalis; Advisory/Consultancy: Janssen Research & Development; Advisory/Consultancy: Merck; Advisory/Consultancy: VBL Therapeutics. E. Guerra: Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy, Travel/Accommodation/Expenses: GlaxoSmithKline; Advisory/Consultancy: PharmaMar; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Merck Sharp & Dohme; Travel/Accommodation/Expenses: Baxter. J. Maenpaa: Honoraria (institution): Tesaro; Honoraria (institution): AstraZeneca; Honoraria (institution): Clovis; Honoraria (institution): Roche; Honoraria (institution): MSD; Honoraria (institution): OrionPharma. E. Bacqué: Full/Part-time employment: GlaxoSmithKline. Y. Li: Full/Part-time employment: GlaxoSmithKline. A. González Martín: Advisory/Consultancy, Non-remunerated activity/ies: AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution), Non-remunerated activity/ies: Tesaro; Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy, Research grant/Funding (institution), Non-remunerated activity/ies: Roche Holding AG; Advisory/Consultancy: Merck & Co. Inc.; Advisory/Consultancy: Genmab; Advisory/Consultancy: Immunogen; Advisory/Consultancy: PharmaMar, S.A; Advisory/Consultancy: Oncoinvent AS. B.J. Monk: Advisory/Consultancy, Research grant/Funding (institution): Tesaro. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.